

ASX Announcement

21 August 2026

**VALIDATION COMPLETED AND COMMERCIAL TESTING COMMENCED
AT HVIDOVRE HOSPITAL IN DENMARK**

Sydney, Australia, Genetic Signatures Limited (ASX: GSS) ("Genetic Signatures" or "the Company") is pleased to advise that the installation and validation of its *EasyScreen*™ Pan-Enteric assay at Hvidovre Hospital, Denmark, has been successfully completed, order for the first quarter supply of tests has been delivered and testing is now underway.

As announced on 15 April 2026, the Company signed a ten-year Reagent and Consumables Supply Agreement and an accompanying Equipment Supply Agreement with Hvidovre Hospital, one of Denmark's leading public hospitals, for gastrointestinal screening using the Company's *EasyScreen*™ Pan-Enteric assay. Successful completion of the customary installation and validation process is a key contractual milestone, confirming that the assay meets Hvidovre Hospital's performance requirements and triggering the activation of full commercial deployment.

Commercial testing has now commenced, with the contract expected to generate testing volumes of approximately 28,000 samples in the first year, with estimated annual growth of 3%. Pricing under the agreement remains commercially sensitive and will not be released publicly.

CEO of Genetic Signatures, Maria Halasz, said: "The successful validation at Hvidovre Hospital is an important milestone, confirming the superior performance of our *EasyScreen*™ Pan-Enteric assay in a demanding clinical environment and activating a ten-year agreement with one of Denmark's leading public hospitals. With validation complete and commercial testing underway, we look forward to Hvidovre realising the diagnostic and operational benefits our pan-enteric approach has delivered in other international markets, and to building on this milestone as we continue to grow our footprint across Europe."

The Company will continue to update the market on the progress of the Hvidovre Hospital contract and its broader EMEA growth strategy in line with its continuous disclosure obligations.

About the *EasyScreen*™ Pan-Enteric Assay

The *EasyScreen*™ Pan-Enteric assay, powered by Genetic Signatures' patented 3base® technology, enables simultaneous detection of 24 gastrointestinal pathogens, including bacteria, viruses, and parasites, from a single patient sample in one automated run. The assay is designed for high-throughput clinical laboratories seeking to improve diagnostic accuracy, reduce complexity, and deliver faster, more comprehensive and clinically actionable results to support better patient outcomes.

About Genetic Signatures Limited

Genetic Signatures Limited (ASX: GSS) is an Australian molecular diagnostics company focused on the development and commercialisation of molecular detection products for infectious diseases. The Company's proprietary 3base® technology platform simplifies the detection of pathogens, offering superior sensitivity and specificity across a broad range of clinical applications. Genetic Signatures markets its *EasyScreen*™ range of diagnostic assays globally, with a growing commercial presence across Europe, the United Kingdom, and the Asia-Pacific region.

– END –

Announcement authorised by Genetic Signatures' Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Maria Halasz
Chief Executive Officer
maria.halasz@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures Limited:

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.